Literature DB >> 33716736

Sodium Houttuyfonate Inhibits Bleomycin Induced Pulmonary Fibrosis in Mice.

Yun-Hui Shen1, Ming-Han Cheng2, Xin-Yu Liu1, De-Wei Zhu1, Jian Gao2.   

Abstract

Pulmonary fibrosis (PF) could severely disrupt the normal lung architecture and function with fatal consequences. Currently, there is no effective treatment for PF or idiopathic pulmonary fibrosis (IPF). The aim of this study was to investigate the effects of Sodium Houttuyfonate (SH) on bleomycin (BLM) induced PF mice model. Our results indicated that SH could attenuate BLM induced lung injury by reducing the inflammation, fibrogenesis and lung/body weight ratio. The proposed mechanisms for the protective effects of SH include: 1) improvement of pulmonary function in BLM mice, for instance, it can elevate the vital capacity (VC), increase the forced expiratory flow at 50% of forced vital capacity (FEF50) and improve other pulmonary function indices; 2) inhibition of collagen formation in BLM mice; 3) attenuation of the elevation of inflammatory cytokines, such as interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α), which are triggered by BLM administration; 4) reduction of the mRNA level and protein production of transforming growth factor-β1 (TGF-β1) in BLM mice. Furthermore, it was found that the protective effects of SH against BLM induced PF in mice was comparable to that of prednisone acetate (PA) tablets, a widely used drug for immunological diseases. Although Houttuynia Cordata Thunb has been widely used in China for lung infection and inflammation, the mechanism has not yet been fully elucidated. Our study provides the evidence that SH is an effective compound against pulmonary injury, irritation and fibrogenesis.
Copyright © 2021 Shen, Cheng, Liu, Zhu and Gao.

Entities:  

Keywords:  Smad; bleomycin; pulmonary fibrosis; pulmonary function; sodium houttuyfonate; transforming growth factor-β (TGF-β)

Year:  2021        PMID: 33716736      PMCID: PMC7947865          DOI: 10.3389/fphar.2021.596492

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  51 in total

Review 1.  Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment.

Authors:  P J Sime; K M O'Reilly
Journal:  Clin Immunol       Date:  2001-06       Impact factor: 3.969

Review 2.  Modeling pulmonary fibrosis with bleomycin.

Authors:  Marios A Mouratis; Vassilis Aidinis
Journal:  Curr Opin Pulm Med       Date:  2011-09       Impact factor: 3.155

Review 3.  Molecular targets in pulmonary fibrosis: the myofibroblast in focus.

Authors:  Chris J Scotton; Rachel C Chambers
Journal:  Chest       Date:  2007-10       Impact factor: 9.410

Review 4.  [Mechanisms in pulmonary fibrosis].

Authors:  Bruno Crestani; Sylvain Marchand-Adam; Aurélie Fabre; Monique Dehoux; Paul Soler
Journal:  Rev Prat       Date:  2007-12-31

5.  Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model.

Authors:  Nveed I Chaudhary; Andreas Schnapp; John E Park
Journal:  Am J Respir Crit Care Med       Date:  2006-01-13       Impact factor: 21.405

6.  Mangiferin attenuates bleomycin-induced pulmonary fibrosis in mice through inhibiting TLR4/p65 and TGF-β1/Smad2/3 pathway.

Authors:  Li Jia; Ping Sun; Hui Gao; Jie Shen; Yuan Gao; Cheng Meng; Shidong Fu; Huijuan Yao; Gong Zhang
Journal:  J Pharm Pharmacol       Date:  2019-03-07       Impact factor: 3.765

7.  Costunolide inhibits pulmonary fibrosis via regulating NF-kB and TGF-β1/Smad2/Nrf2-NOX4 signaling pathways.

Authors:  Bin Liu; Yumei Rong; Dan Sun; Wuwei Li; Hong Chen; Bo Cao; Taoyuan Wang
Journal:  Biochem Biophys Res Commun       Date:  2019-01-29       Impact factor: 3.575

8.  Sodium houttuyfonate enhances the intestinal barrier and attenuates inflammation induced by Salmonella typhimurium through the NF-κB pathway in mice.

Authors:  Lei Zhang; Hao Lv; Ying Li; Na Dong; Chongpeng Bi; Anshan Shan; Zhihan Wu; Baoming Shi
Journal:  Int Immunopharmacol       Date:  2020-10-09       Impact factor: 4.932

9.  Role of Macrophages in Acute Lung Injury and Chronic Fibrosis Induced by Pulmonary Toxicants.

Authors:  Debra L Laskin; Rama Malaviya; Jeffrey D Laskin
Journal:  Toxicol Sci       Date:  2019-04-01       Impact factor: 4.849

10.  Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model.

Authors:  Moisés Selman; Annie Pardo
Journal:  Am J Respir Crit Care Med       Date:  2014-05-15       Impact factor: 21.405

View more
  5 in total

1.  Catalpol Attenuates Pulmonary Fibrosis by Inhibiting Ang II/AT1 and TGF-β/Smad-Mediated Epithelial Mesenchymal Transition.

Authors:  Qun Yu; Dewei Zhu; Yang Zou; Kai Wang; Peili Rao; Yunhui Shen
Journal:  Front Med (Lausanne)       Date:  2022-05-24

2.  Exploring the Anti-Pulmonary Fibrosis Mechanism of Jingyin Granule by Network Pharmacology Strategy.

Authors:  De-Wei Zhu; Qun Yu; Mei-Fang Jiang; Dan-Dan Wang; Yun-Hui Shen
Journal:  Front Pharmacol       Date:  2022-02-11       Impact factor: 5.810

3.  Identifying Active Substances and the Pharmacological Mechanism of Houttuynia cordata Thunb. in Treating Radiation-Induced Lung Injury Based on Network Pharmacology and Molecular Docking Verification.

Authors:  Gui-Hua Lai; Fei Wang; Duo-Rui Nie; Shu-Jun Lei; Zhuo-Jun Wu; Jian-Xiong Cao
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-22       Impact factor: 2.629

4.  Blueberry Juice Attenuates Pulmonary Fibrosis via Blocking the TGF-β1/Smad Signaling Pathway.

Authors:  Yali Li; Liqun Wang; Qianyu Zhang; Li Tian; Cailing Gan; Hongyao Liu; Wenya Yin; Tinghong Ye
Journal:  Front Pharmacol       Date:  2022-03-28       Impact factor: 5.810

5.  Inflammatory and proapoptotic effects of inhaling gasoline fumes on the lung and ameliorative effects of fenugreek seeds.

Authors:  Abeer E Abdrabouh
Journal:  Sci Rep       Date:  2022-08-24       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.